Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

Figure 2 Electromechanical properties of OIHPs

Advertisements

Figure 6 Selected examples of TERS applications in material systems

Copyright © 2004 American Medical Association. All rights reserved.

Figure 3 The induction of anti-DNA antibodies by bacterial DNA

Figure 3 Connexins in cartilage

Figure 5 Involvement of B cells in SLE

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 2 Representative MSI data obtained from human joints

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Structure of TNF antagonists

Figure 2 Risk factors for sarcopenia

Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors

Nat. Rev. Neurol. doi: /nrneurol

Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.

Figure 2 Heat map of targeted therapies in autoimmune diseases

Figure 2 Expression of complement activation products in renal samples

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 3 Nucleic acid sensors in SLE

Figure 1 Location of HLA variants known to be associated

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Supplementary Figure 1. Longitudinal study in a representative number of SLE patients one year before (t1), at the time (t2), and one year after renal.

Figure 3 Endogenous repair of double-strand DNA breaks

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Approaches to targeting inhibitory immune receptors

Figure 4 Post-test probability as a function of pre-test

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 IFA testing for identifying the presence of ANAs

Figure 2 Cas9 targeting using crRNA (CRISPR

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Adaptive immune system of bacteria and archaea

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 The current model of the pathogenesis of SLE

Jack C. O’Brien, Benjamin F. Chong

Figure 6 Metabolism of pterins

Figure 1 Reproductive health in patients with rheumatic diseases

Nat. Rev. Mater. doi: /natrevmats

Figure 1 The release of DNA from dead and dying cells

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Figure 1 Chronic inflammation and DNA damage in people with SLE

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 1 Overview of the imaging biomarker roadmap

Jack C. O’Brien, Benjamin F. Chong

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Positivity rate for antibodies to double-stranded DNA (anti-dsDNA), low complement, high complement C4 activation products (CBCAPS) and two-tiered methodology.

Complement and antibody abnormalities at baseline and relation to disease activity clinical SELENA-SLEDAI (A) and PGA scores (B) in relation to the presence.

Nat. Rev. Rheumatol. doi: /nrrheum

Percentages of 256 clinical isolates obtained from immunocompetent and immunocompromised patients (HIV positive) and from patients with other risk factors.

Nat. Rev. Rheumatol. doi: /nrrheum

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.151 Figure 2 The relationship between IgG antibodies and double-stranded DNA Figure 2 | The relationship between IgG antibodies and double-stranded DNA. Binding of IgG antibodies to DNA can occur by monogamous bivalency, wherein both Fab sites of an IgG molecule make contact with a single stretch of DNA. The distance of 136 Å is equivalent to 40 bp in B-form DNA. Permission obtained from the American Society for Clinical Investigation © Papalian, M. et al. Reaction of systemic lupus erythematosus antinative DNA antibodies with native DNA fragments from 20 to 1,200 base pairs. J. Clin. Invest. 65, 469–477 (1980). Permission obtained from the American Society for Clinical Investigation © Papalian, M. et al. Reaction of systemic lupus erythematosus antinative DNA antibodies with native DNA fragments from 20 to 1,200 base pairs. J. Clin. Invest. 65, 469–477 (1980) Pisetsky, D. S. (2015) Anti-DNA antibodies — quintessential biomarkers of SLE Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.151